Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Evaluation of Brain Targeting Potential of Zolmitriptan Mucoadhesive Nanoparticles for Intranasal Drug Delivery

Author(s): Sunena Jha* and Dinanath Mishra

Volume 10, Issue 2, 2022

Published on: 22 April, 2022

Page: [113 - 124] Pages: 12

DOI: 10.2174/2211738510666220303160414

Price: $65

Abstract

Background: Hydrophilic drugs are poor applicants for brain targeting via oral route due to the presence of a blood-brain barrier that allows only small lipophilic molecules to freely access the brain. Due to unique anatomical connections between the nasal cavity and the brain, intranasal administration can be explored for drug delivery to the brain directly that circumvents the blood-brain barrier too.

Objectives: Zolmitriptan is a widely used antimigraine drug, and its brain targeting by nasal route in the form of mucoadhesive nanoparticles is more effective in migraine treatment as it provides fast relief and good bioavailability as compared to its oral drug delivery. In the present study, zolmitriptan mucoadhesive nanoparticles were prepared to improve the bioavailability and brain targeting for the better management of Migraine attacks.

Methods: The mucoadhesive polymeric nanoparticles of zolmitriptan were formulated by a modified ionic gelation method using thiolated chitosan. The pharmacokinetic parameters were counted in male Wistar rats by intranasal and oral delivery of the anti-migraine drug zolmitriptan and compared statistically. The concentration of zolmitriptan in the blood plasma and brain samples was determined by using the liquid-liquid extraction method followed by a reversed-phase highperformance liquid chromatography (RP-HPLC) analysis. The pharmacodynamic analysis was conducted in adult male Swiss albino mice by behavioral models, a light/dark box model, and acetic acid-induced writhing (abdominal stretching or constriction). These tests were used to reproduce the important associated symptoms of migraine viz. hyperalgesia (nociceptive sensitization) and photophobia to assess the therapeutic potential of intranasal delivery of nanoparticles antimigraine activity.

Results: The absolute bioavailability accessed for Zolmitriptan nanoparticles by IN route was found to be very high (193%), suggesting that the sufficient amount of drug transported by nanoparticles and DTE ratio was calculated as 2.8. Moreover, it revealed better nose-to-brain transport by zolmitriptan nanoparticles as compared to oral delivery in male Wistar rats. A significant increase in the tolerance capacity of animals to bright light and a fall in the number of stretching in mice suggested the better management of migraine-associated symptoms by the zolmitriptan nanoparticles.

Conclusion: Thus, the present study confers the significance of nasal drug delivery for brain targeting of zolmitriptan nanoparticles for the treatment of migraine.

Keywords: Zolmitriptan, nanoparticles, intranasal, mucoadhesive, thiolated chitosan, brain targeting, migraine.

Next »
Graphical Abstract

[1]
Belvís R, Pagonabarraga J, Kulisevsky J. Individual triptan selection in migraine attack therapy. Recent Patents CNS Drug Discov 2009; 4(1): 70-81.
[http://dx.doi.org/10.2174/157488909787002555] [PMID: 19149716]
[2]
Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: A systematic review. Headache 2019; 59(3): 306-38.
[http://dx.doi.org/10.1111/head.13459] [PMID: 30589090]
[3]
Hamel E, Currents H. Serotonin and migraine: Biology and clinical implications. Cephalalgia 2007; 27(11): 1293-300.
[http://dx.doi.org/10.1111/j.1468-2982.2007.01476.x] [PMID: 17970989]
[4]
Girotra P, Singh SK, Saini D. Disentangling the intricacies of migraine: A review. CNS Neurol Disord Drug Targets 2014; 13(5): 776-91.
[http://dx.doi.org/10.2174/1871527313666140414120956] [PMID: 24725087]
[5]
Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care 2019; 25(2)(Suppl.): S23-34.
[PMID: 30681821]
[6]
Deen M, Hougaard A, Hansen HD, et al. Migraine is associated with high brain 5-HT levels as indexed by 5-HT4 receptor binding. Cephalalgia 2019; 39(4): 526-32.
[http://dx.doi.org/10.1177/0333102418793642] [PMID: 30089402]
[7]
Glen RC, Martin GR, Hill AP, et al. Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: Discovery of compounds with potential anti-migraine properties. J Med Chem 1995; 38(18): 3566-80.
[http://dx.doi.org/10.1021/jm00018a016] [PMID: 7658443]
[8]
Ferrari MD. 311C90: Increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists. Neurology 1997; 48(3)(Suppl. 3): S21-4.
[http://dx.doi.org/10.1212/WNL.48.3_Suppl_3.21S] [PMID: 9071266]
[9]
Palmer KJ, Spencer CM. Zolmitriptan. CNS Drugs 1997; 7(6): 468-78.
[http://dx.doi.org/10.2165/00023210-199707060-00005]
[10]
Martin GR, Robertson AD, MacLennan SJ, et al. Receptor specificity and trigemino-vascular inhibito-ry actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 1997; 121(2): 157-64.
[http://dx.doi.org/10.1038/sj.bjp.0701041] [PMID: 9154322]
[11]
Bayrak Z, Tas C, Tasdemir U, et al. Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2011; 78(3): 499-505.
[http://dx.doi.org/10.1016/j.ejpb.2011.02.014] [PMID: 21352916]
[12]
Desu P, Sahu M. Formulation and evaluation of fast dissolving films of zolmitriptan. Int Res J Pharm 2012; 2012(3): 373-6.
[13]
Bankim CN, Gupta AK, Mittal A, Mohd KZ. Design and development of solid dispersion system of zolmitriptan. J Biomed Pharm Res 2013; 2: 7-13.
[14]
Niranjan P, Reddy AV, Reddy GVS, Panda KC. Formulation, design and in vitro evaluation of zolmitriptan immediate release tablets using Primojel and AC-Di-Sol. J Pharm Sci Res 2015; 7(8): 545-53.
[15]
Patil PR, Salve VK, Thorat RU, Shahi SR. Formulation and evaluation of ion-sensitive in-situ nasal gel of zolmitriptan. Int J Pharma Sci 2015; 7: 478-86.
[16]
Sweetman SC. The Martindale: The Complete Drug Reference. 35th ed. Vol: USA: Pharmaceutical Press. 2007.
[17]
Alhalaweh A, Andersson S, Velaga SP. Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery. Eur J Pharm Sci 2009; 38(3): 206-14.
[http://dx.doi.org/10.1016/j.ejps.2009.07.003] [PMID: 19616094]
[18]
Sachan N, Bahadur S, Sharma PK. Recent advances and novel approaches for nose to brain drug de-livery for treatment of migraine. Drug Deliv Lett 2019; 9(3): 182-98.
[http://dx.doi.org/10.2174/2210303109666190508083142]
[19]
Uemura N, Onishi T, Mitaniyama A, et al. Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Investig 2005; 25(3): 199-208.
[http://dx.doi.org/10.2165/00044011-200525030-00006] [PMID: 17523769]
[20]
Dowson AJ, Charlesworth B. Review of zolmitriptan and its clinical applications in migraine. Expert Opin Pharmacother 2002; 3(7): 993-1005.
[http://dx.doi.org/10.1517/14656566.3.7.993] [PMID: 12083998]
[21]
Dixon R, Warrander A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997; 17(18)(Suppl. 18): 15-20.
[http://dx.doi.org/10.1177/0333102497017S1803] [PMID: 9399013]
[22]
Ahonen K, Hämäläinen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of mi-graine attacks in children: A randomized trial. Neurology 2004; 62(6): 883-7.
[http://dx.doi.org/10.1212/01.WNL.0000115105.05966.A7] [PMID: 15037686]
[23]
Goadsby PJ, Yates R. Zolmitriptan intranasal: A review of the pharmacokinetics and clinical efficacy. Headache 2006; 46(1): 138-49.
[http://dx.doi.org/10.1111/j.1526-4610.2006.00301.x] [PMID: 16412161]
[24]
Egla M. Abd Al, Hammid SN. Design zolmitriptan liquisolid orodispersible tablets and their in vitro evaluation. Int J Pharma Sci 2017; 9(1): 297-303.
[25]
Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: Current status and future perspective. Drug Deliv 2014; 21(2): 75-86.
[http://dx.doi.org/10.3109/10717544.2013.838713] [PMID: 24102636]
[26]
Gulati N, Nagaich U, Saraf SA. Intranasal delivery of chitosan nanoparticles for migraine therapy. Sci Pharm 2013; 81(3): 843-54.
[http://dx.doi.org/10.3797/scipharm.1208-18] [PMID: 24106677]
[27]
Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci 2010; 99(4): 1654-73.
[http://dx.doi.org/10.1002/jps.21924] [PMID: 19877171]
[28]
Pires A, Fortuna A, Alve G, Falcao A. Intranasal drug delivery: How, why and what for? J Pharm Pharm Sci 2009; 12(3): 288-311.
[29]
Sunena M, Singh SK, Mishra DN. Nose to brain delivery of galantamine loaded nanoparticles: In-vivo pharmacodynamic and biochemical study in mice. Curr Drug Deliv 2019; 16(1): 51-8.
[http://dx.doi.org/10.2174/1567201815666181004094707] [PMID: 30289074]
[30]
Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47(1): 65-81.
[http://dx.doi.org/10.1016/S0169-409X(00)00122-8] [PMID: 11251246]
[31]
Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009; 379(1): 146-57.
[http://dx.doi.org/10.1016/j.ijpharm.2009.06.019] [PMID: 19555750]
[32]
Far J, Abdel-Haq M, Gruber M, Abu Ammar A. Developing biodegradable nanoparticles loaded with mometasone furoate for potential nasal drug delivery. ACS Omega 2020; 5(13): 7432-9.
[http://dx.doi.org/10.1021/acsomega.0c00111] [PMID: 32280885]
[33]
Esim O, Savaser A, Ozkan CK, et al. Nose to brain delivery of eletriptan hydrobromide nanoparticles: Preparation, in vitro/in vivo evaluation and effect on trigeminal activation. J Drug Deliv Sci Technol 2020; 59, 101919.
[http://dx.doi.org/10.1016/j.jddst.2020.101919]
[34]
Bhanushali RS, Gatne MM, Gaikwad IRV, Bajaj AN, Morde MA. Nanoemulsion based intranasal delivery of antimigraine drugs for nose to brain targeting. Indian J Pharm Sci 2009; 71: 707-9.
[35]
Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 2016; 6(4): 268-86.
[http://dx.doi.org/10.1016/j.apsb.2016.05.013] [PMID: 27471668]
[36]
Ruan S, Zhou Y, Jiang X, Gao H. Rethinking CRITID procedure of brain targeting drug delivery: Circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internaliza-tion, and drug release. Adv Sci (Weinh) 2021; 8(9), 2004025.
[http://dx.doi.org/10.1002/advs.202004025] [PMID: 33977060]
[37]
Girotra P, Singh SK. Chitosan: An emanating polymeric carrier for drug delivery.In: Thakur VK, Thakur MK, Eds. . Handbook of Polymers for Pharmaceutical Technologies Wiley: Scrivener Publish-ing LLC. 2015; pp. 33-60.
[http://dx.doi.org/10.1002/9781119041450.ch2]
[38]
Smith J, Wood E, Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm Res 2004; 21(1): 43-9.
[http://dx.doi.org/10.1023/B:PHAM.0000012150.60180.e3] [PMID: 14984256]
[39]
Bernkop-Schnürch A, Schwarz V, Steininger S. Polymers with thiol groups: A new generation of mu-coadhesive polymers? Pharm Res 1999; 16(6): 876-81.
[http://dx.doi.org/10.1023/A:1018830204170] [PMID: 10397608]
[40]
Bernkop-Schnürch A, Hornof M, Guggi D. Thiolated chitosans. Eur J Pharm Biopharm 2004; 57(1): 9-17.
[http://dx.doi.org/10.1016/S0939-6411(03)00147-4] [PMID: 14729077]
[41]
Rana D, Bag K, Bhattacharyya SN, Mandal BM. Miscibility of poly(styrene-co-butyl acrylate) with poly(ethyl methacrylate): Existence of both UCST and LCST. J Polym Sci, B, Polym Phys 2000; 38(3): 369-75.
[http://dx.doi.org/10.1002/(SICI)1099-0488(20000201)38:3<369::AID-POLB3>3.0.CO;2-W]
[42]
Rana D, Mandal BM, Bhattacharyya SN. Analogue calorimetry of polymer blends: Poly(styrene-co-acrylonitrile) and poly(phenyl acrylate) or poly(vinyl benzoate). Polymer (Guildf) 1996; 37(12): 2439-43.
[http://dx.doi.org/10.1016/0032-3861(96)85356-0]
[43]
Rana D, Mandal BM, Bhattacharyya SN. Miscibility and phase diagrams of poly(phenyl acrylate) and poly(styrene-co-acrylonitrile) blends. Polymer (Guildf) 1993; 34(7): 1454-9.
[http://dx.doi.org/10.1016/0032-3861(93)90861-4]
[44]
Rana D, Mandal BM, Bhattacharyya SN. Analogue calorimetric studies of blends of poly (vinyl ester) and polyacrylates. Macromolecules 1996; 29(5): 1579-83.
[http://dx.doi.org/10.1021/ma950954n]
[45]
Bernkop-Schnürch A, Heinrich A, Greimel A. Development of a novel method for the preparation of submicron particles based on thiolated chitosan. Eur J Pharm Biopharm 2006; 63(2): 166-72.
[http://dx.doi.org/10.1016/j.ejpb.2006.01.002] [PMID: 16527469]
[46]
El-Nabarawy NA, Teaima MH, Helal DA. Assessment of spanlastic vesicles of zolmitriptan for treat-ing migraine in rats. Drug Des Devel Ther 2019; 13: 3929-37.
[http://dx.doi.org/10.2147/DDDT.S220473] [PMID: 31819367]
[47]
Munro G, Jansen-Olesen I, Olesen J. Animal models of pain and migraine in drug discovery. Drug Discov Today 2017; 22(7): 1103-11.
[http://dx.doi.org/10.1016/j.drudis.2017.04.016] [PMID: 28476535]
[48]
Tardiolo G, Bramanti P, Mazzon E. Migraine: Experimental models and novel therapeutic approaches. Int J Mol Sci 2019; 20(12): 2932.
[http://dx.doi.org/10.3390/ijms20122932] [PMID: 31208068]
[49]
Sunena, Mishra DN, Singh SK, Kumar A. Synthesis, characterization and in vitro evaluation of muco-adhesive potential of thiolated chitosan. Inter J Pharma Prof Res 2016; 7(5): 1341-5.
[50]
Sunena, Mishra DN, Singh SK, Kumar A. Formulation and optimization of mucoadhesive galanta-mine loaded nanoparticles. Pharm Lett 2016; 8(10): 206-12.
[51]
Sunena, Mishra DN, Singh SK, Kumar A. Development and characterization of zolmitriptan thiolated chitosan nanoparticles for intranasal drug delivery. Pharma Innov J 2016; 5(7): 19-23.
[52]
Sunena Jalwal P. Nose to brain drug delivery of nanoformulations in the treatment of migraine. Pharma Innovation Journal 2020; 9(12): 248-53.
[53]
Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromole-cules. Adv Drug Deliv Rev 2001; 47(1): 83-97.
[http://dx.doi.org/10.1016/S0169-409X(00)00123-X] [PMID: 11251247]
[54]
Prabaharan M, Mano JF. Chitosan-based particles as controlled drug delivery systems. Drug Deliv 2005; 12(1): 41-57.
[http://dx.doi.org/10.1080/10717540590889781] [PMID: 15801720]
[55]
Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release 2014; 189: 133-40.
[http://dx.doi.org/10.1016/j.jconrel.2014.06.053] [PMID: 24997277]
[56]
Wang F, Jiang X, Lu W. Profiles of methotrexate in blood and CSF following intranasal and intrave-nous administration to rats. Int J Pharm 2003; 263(1-2): 1-7.
[http://dx.doi.org/10.1016/S0378-5173(03)00341-7] [PMID: 12954175]
[57]
Zheng T, Bott S, Huo Q. Techniques for accurate sizing of gold nanoparticles using dynamic light scattering with particular application to chemical and biological sensing based on aggregate formation. ACS Appl Mater Interfaces 2016; 8(33): 21585-94.
[http://dx.doi.org/10.1021/acsami.6b06903] [PMID: 27472008]
[58]
Saremi S, Atyabi F, Akhlaghi SP, Ostad SN, Dinarvand R. Thiolated chitosan nanoparticles for en-hancing oral absorption of docetaxel: Preparation, in vitro and ex vivo evaluation. Int J Nanomedicine 2011; 6: 119-28.
[PMID: 21289989]
[59]
Lee CA, Kim BS, Cho CW. Quantitative evaluation of mucoadhesive polymers to compare the muco-adhesion. J Pharm Investig 2016; 46(2): 189-94.
[http://dx.doi.org/10.1007/s40005-016-0233-4]
[60]
Thirawong N, Nunthanid J, Puttipipatkhachorn S, Sriamornsak P. Mucoadhesive properties of various pectins on gastrointestinal mucosa: An in vitro evaluation using texture analyzer. Eur J Pharm Biopharm 2007; 67(1): 132-40.
[http://dx.doi.org/10.1016/j.ejpb.2007.01.010] [PMID: 17321731]
[61]
Okamoto K, Thompson R, Tashiro A, Chang Z, Bereiter DA. Bright light produces Fos-positive neu-rons in caudal trigeminal brainstem. Neuroscience 2009; 160(4): 858-64.
[http://dx.doi.org/10.1016/j.neuroscience.2009.03.003] [PMID: 19285114]
[62]
Vuralli D, Wattiez AS, Russo AF, Bolay H. Behavioral and cognitive animal models in headache re-search. J Headache Pain 2019; 20(11), s10194.
[http://dx.doi.org/10.1186/s10194-019-0963-6]
[63]
Nikai T, Basbaum AI, Ahn AH. Profound reduction of somatic and visceral pain in mice by intrathe-cal administration of the anti-migraine drug, sumatriptan. Pain 2008; 139(3): 533-40.
[http://dx.doi.org/10.1016/j.pain.2008.06.002] [PMID: 18723285]
[64]
Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004; 56(3): 371-81.
[http://dx.doi.org/10.1002/ana.20193] [PMID: 15349864]

Rights & Permissions Print Cite
Article Metrics
30
1
© 2024 Bentham Science Publishers | Privacy Policy